Compare Alnylam Pharmaceuticals, Inc. (ALNY) vs MakeMyTrip Ltd (MMYT) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Alnylam Pharmaceuticals, Inc. vs MakeMyTrip Ltd — how do they compare? Alnylam Pharmaceuticals, Inc. trades at $300.02 (market cap $39.89B), while MakeMyTrip Ltd trades at $58.5 (market cap $5.56B). The key difference: Alnylam Pharmaceuticals, Inc. is far larger — about 7.2× MakeMyTrip Ltd's market cap, and MakeMyTrip Ltd is trading nearer its 52-week high, Alnylam Pharmaceuticals, Inc. nearer its low. Which is the better fit depends on your goals.
| ALNY | MMYT | |
|---|---|---|
Market Cap | $39.89B | $5.56B |
Sector | Health | Technology |
52-Week High | $491.22 | $103.21 |
52-Week Low | $278.09 | $36.30 |
Enterprise Value | $38.15B | $6.20B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ALNY trades at $298.76, down 4.49% today, but maintains a bullish technical outlook with strong support at $290. The company reported robust revenue growth to $3.71 billion in 2025, turning profitable with net income of $313.75 million. Analyst consensus is strongly bullish with a $429.50 price target, supported by positive news on drug pipelines and AI partnerships.
Outlook remains positive driven by expanding product portfolio and strategic collaborations, though risks include clinical trial outcomes and high valuation multiples. Earnings beats in recent quarters reinforce growth trajectory, but dependence on key drug Amvuttra and competitive pressures warrant monitoring for sustained shareholder value.
MMYT trades at $58.62, up 1.03% today, with a bullish technical signal from moving averages. The company reported strong earnings beats in recent quarters, with Q1 2026 EPS of $0.25 exceeding expectations. Revenue reached $978.34 million in 2025, though net income margin is projected to narrow to 4.96% in 2026. Analyst consensus is strongly positive with 72.73% buy ratings. Recent news highlights temporary travel disruptions but maintains confidence in long-term growth.
The outlook remains favorable given consistent earnings outperformance and robust analyst support, but risks include projected margin compression and rising debt levels. Investors should weigh strong operational cash flow against potential volatility from travel industry headwinds and increasing liabilities in the coming year.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia.
Read more on ALNY →About MakeMyTrip Ltd
MakeMyTrip Ltd. is a leading online travel company in India, providing a comprehensive range of travel services and products, including air tickets, hotels, holiday packages, rail tickets, and bus tickets. The company operates its primary websites and mobile apps under the brands MakeMyTrip, Goibibo, and RedBus. MMYT serves as a key intermediary in India's fragmented travel market, leveraging its platform to offer convenience and competitive pricing to consumers and businesses.
Read more on MMYT →
